Q4 2016 13F Holders as of 12/31/2016
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
36.7M
-
Shares change
-
-1.06M
-
Total reported value, excl. options
-
$1.88B
-
Value change
-
-$47.8M
-
Put/Call ratio
-
1.24
-
Number of buys
-
88
-
Number of sells
-
-62
-
Price
-
$51.06
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q4 2016
196 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q4 2016.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.7M shares
of 62.7M outstanding shares and own 58.63% of the company stock.
Largest 10 shareholders include FMR LLC (5.58M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.56M shares), VANGUARD GROUP INC (2.43M shares), OppenheimerFunds, Inc. (1.94M shares), BlackRock Fund Advisors (1.42M shares), STATE STREET CORP (1.16M shares), FRANKLIN RESOURCES INC (1.12M shares), BB BIOTECH AG (1.02M shares), OAK RIDGE INVESTMENTS LLC (1.01M shares), and Palo Alto Investors, LLC (1.01M shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.